Taconic Biosciences Expands Access to rasH2 Carcinogenicity Testing System in Asia PacificFour-Way Distribution Partnership Provides Consistent, Quality RasH2 Supply to India and China, Better Serving Customers global

RENSSELAER, NY, March 21, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences (formerly known as Taconic Farms, Inc.), a global leader in providing animal model solutions for drug discovery, has appointed Nomura Siam International Co., Ltd. (NSI) and Nomura Jimusho. Inc. (NJI) as the sales agents and distributors of mouse rasH2 carcinogenicity test system in India and China, respectively. These distribution agreements significantly improve access to rasH2 for the burgeoning pharmaceutical industry in the Asia-Pacific region.

the rasH2 transgenic mouse model is the only short-term (6 month) carcinogenicity test system that is both accepted by global regulatory authorities and readily available in commercial production. Invented by the Central Institute for Experimental Animals (CIEA), the rasH2 model is widely used as an alternative to the 2-year carcinogenicity bioassay, providing a faster and more accurate testing system that better aligns with Russell’s 3R principles & Burch. Taconic and CLEA Japan, Inc (CLEA) have provided validated and consistent rasH2 mice for use in North America, Europe and Asia since 2006, although access in India and China has been limited. As drug discovery and development activity increases in India and China, access to a carcinogenicity test accepted by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well only by local authorities, is vital.

Under the new agreement, NSI serves as sales agent and distributor for India and NJI as sales agent and distributor for China. These distributors and sales agents greatly simplify the transaction process for users located in these countries. NSI and NJI will leverage CLEA and Taconic production colonies in Japan, Denmark and the United States to meet customer demand, making it easier for investigators to access. Taconic, CLEA and CIEA closely monitor these colonies and perform regular functional studies using positive control compounds to ensure performance essential for drug safety evaluation. The arrangement also allows CLEA and Taconic to align production to meet global demand through better visibility into global rasH2 usage and needs.

“The rasH2 model has delivered on the promise of transgenic technology by demonstrating exceptional value in evaluating the carcinogenicity of new drugs, and the global adoption of this system is testament to its advantages in terms of speed, specificity and cost. total,” said Dr. Michael Seiler, Vice President of Commercial Products at Taconic.

“This landmark collaboration ensures customers in every country have full access to the rasH2 carcinogenicity testing system,” said Ryuta Nomura, Chairman of the Board and CEO of CIEA. “This partnership will dramatically increase the likelihood that all customers worldwide will receive rasH2 as requested with minimal delay, allowing studies to be completed sooner and ultimately helping bring new drugs to market faster.” vital.

For more information on the rasH2 model, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email [email protected].

About Taconic Biosciences, Inc.

Taconic Biosciences is a licensed global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so customers can acquire, custom generate, breed, precondition, test and distribute valuable research models worldwide. Specializing in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the United States and Europe, maintains distribution relationships in Asia and has global shipping capabilities to supply animal models almost anywhere in the world.

About CIEA:

The Central Institute for Experimental Animals is a private, independent, non-profit institute founded in 1952 to contribute to medical care and medical science based on animal experimentation.

About CLEA:

CLEA Japan Inc. was founded in 1965 as a complete system supplier of laboratory animals, their feed and equipment, to support bioscience research and development with a vision of health, welfare -being and the environment for humans.

CLEA operates four breeding facilities in Japan, a joint venture in Thailand and a technical service center near Mount Fuji in Japan.

OnNomura Siam International Co. Ltd. (NSI):

Nomura Siam International Co. Ltd., based in Bangkok, Thailand, was jointly established in 2012 by CLEA Japan, Inc. and Nomura Jimusho, Inc. to provide one-stop service in laboratory animal field. As a one-stop service provider, NSI not only sells laboratory animals, but also handles a wide range of related products, including equipment for animal husbandry and experiments, food and bedding. , as well as consulting services for preclinical research and the design of laboratory animal facilities.

About Nomura Jimusho. Inc. (INM):

Established in 1933 for petroleum-related businesses and diversified business to process products with unique and distinct characteristics in areas such as petroleum refining catalysts, specialty materials, plastic containers, specialty chemicals and science of life. In the field of life science, NJI/NSI has been supplying laboratory animals and various laboratory animal equipment for over a decade to overseas markets, such as China, Korea, Thailand, Singapore, Indonesia, Malaysia and recently India as part of a partnership with Taconic Biosciences. , Inc.

Media Contact:

Aidan Bouchelle
Associate Director, Marketing Operations
[email protected]

main logo

Comments are closed.